Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-Z IGF1R:4551

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 90-97

  Tolmachev, Vladimir ^a   Malmberg, Jennie ^b   Hofström, Camilla ^c   Abrahmsén, Lars ^d   Bergman, Thomas ^d   Sjöberg, Anna ^d   Sandström, Mattias ^e   Gräslund, Torbjörn ^c   Orlova, Anna ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d Affibody AB   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

111In; Affibody molecule; DU145 xenograft; IGF 1R; Molecular imaging

Indexed keywords

INDIUM 111; RADIOPHARMACEUTICAL AGENT; SOMATOMEDIN C RECEPTOR; TETRAXETAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; FEASIBILITY STUDY; IMAGE ANALYSIS; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION ABSORPTION; RADIOACTIVITY;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEASIBILITY STUDIES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1; RECOMBINANT FUSION PROTEINS;

EID: 84855410318     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.090829     Document Type: Article

References (40)

1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505-518. (Pubitemid 38868620)
2. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem. 2009;115:58-71.
3. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008;114:23-37. (Pubitemid 351998752)
4. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65: 11118-11128. (Pubitemid 41713383)
5. Thomas F, Holly JM, Persad R, Bahl A, Perks CM. Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate. 2010;70:856-865.
6. Wu JD, Haugk K, Coleman I, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 2006;12:6153-6160. (Pubitemid 44703781)
7. Sachdev D, Yee D. Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer. J Mammary Gland Biol Neoplasia. 2006;11: 27-39. (Pubitemid 44309187)
8. Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008;7:2575-2588.
9. Krueckl SL, Sikes RA, Edlund NM, et al. Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res. 2004;64:8620-8629. (Pubitemid 39552075)
10. Pienta KJ, Bradley D. Mechanisms underlying the development of androgenindependent prostate cancer. Clin Cancer Res. 2006;12:1665-1671.
11. Culig Z, Hobisch A, Cronauer MV, et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-5478.
12. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol. 2009;56:594-605.
13. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett. 2010;291:1-13.
14. Zha J, O'Brien C, Savage H, et al. Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther. 2009;8:2110-2121.
15. Cao L, Yu Y, Darko I, et al. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008;68:8039-8048.
16. Gong Y, Yao E, Shen R, et al. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS ONE. 2009;4:e7273.
17. de Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res. 2007;13:3611-3616. (Pubitemid 46955123)
18. Tolmachev V, Stone-Elander S, Orlova A. Current approaches to the use of radiolabeled tyrosine kinase-targeting drugs for patient stratification and treatment response monitoring: prospects and pitfalls. Lancet Oncol. 2010;11:992-1000.
19. Miao Z, Levi J, Cheng Z. Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. 10.1007/s00726-010-0503-9.
20. Grönwall C, Ståhl S. Engineered affinity proteins: generation and applications. J Biotechnol. 2009;140:254-269.
21. Nygren PA. Alternative binding proteins: Affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J. 2008;275:2668-2676.
22. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
23. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol. 2010;11:581-589.
24. 68Ga-labeled Affibody molecules. J Nucl Med. 2010;51:892-897.
25. Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of I-labelled Affibody molecule and trastuzumab in a murine xenograft model. J Nucl Med. 2009;50:417-425.
26. Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, Gräslund T. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem. 2010;55:99-109.
27. Ahlgren S, Orlova A, Rosik D, et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem. 2008;19:235-243. (Pubitemid 351213855)
28. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M, Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods. 2007;319:53-63. (Pubitemid 46107467)
29. 111In-MMA-Cys]Z2377 Affibody molecule: aspect of injected amount. Eur J Nucl Med Mol Imaging. 2010;37:613-622.
30. Heskamp S, van Laarhoven HW, Molkenboer-Kuenen JD, et al. ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565-1572.
31. 125I- labeled des(1-3) insulin- like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res. 1997;57:2754-2759.
32. Sun BF, Kobayashi H, Le N, et al. Effects of insulin-like growth factor binding proteins on insulinlike growth factor-I biodistribution in tumor-bearing nude mice. J Nucl Med. 2000;41:318-326. (Pubitemid 30091354)
33. 111In- IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol. 2008;35:645-653.
34. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945. (Pubitemid 46657438)
35. 99mTc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem. 2010;21:2013-2022.
36. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging. 2009;36:692-701.
37. 99mTc-labeled recombinant Affibody molecules improves their biodistribution and imaging properties. J Nucl Med. 2011;52:461-469.
38. Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med. 2009;7:263-274.
39. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007; 13:2795-2803. (Pubitemid 46788049)
40. Knowlden JM, Jones HE, Barrow D, Gee JM, Nicholson RI, Hutcheson IR. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat. 2008;111:79-91. (Pubitemid 352009232)